Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Repare Therapeutics Inc (RPTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Repare's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.535 +0.015    +0.99%
08/08 - Closed. Currency in USD
After Hours
1.500
-0.035
-2.280%
22:12:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 199,225
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.480 - 1.560
Repare 1.535 +0.015 +0.99%

Repare Therapeutics Inc Company Profile

 
Get an in-depth profile of Repare Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

129

Equity Type

ORD

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

Contact Information

Address 7171 Frederick-Banting, Building 2 Suite 270
St-Laurent Montreal, H4S 1Z9
Canada
Phone 857-412-7018
Fax -

Top Executives

Name Age Since Title
Samarth Kulkarni 47 2019 Independent Director
David Bonita 49 2019 Independent Director
Ann D. Rhoads 60 2020 Independent Director
Susan M. Molineaux 71 2023 Independent Director
Carol A. Schafer 60 2019 Independent Director
Thomas Civik 56 2021 Independent Chairman
Steve Forte 46 2019 President, CFO, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RPTX Comments

Write your thoughts about Repare Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email